Recent studies report an interesting role of Peroxisome Proliferator-Activated Receptors (PPAR) antagonists in different tumor models, being these compounds able to perturb metabolism and viability in cancer cells. In this work the identification of a novel PPAR antagonist, showing inhibitory activity on PPARa and a weaker antagonism on PPARg, is described. The activity of this compound and of a series of chemical analogues was investigated in selected tumor cell lines, expressing both PPARa and PPARg. Data obtained show a dose-dependent cytotoxic effect of the novel PPAR antagonist in colorectal and pancreatic cancer models.
Cytotoxic effect of a family of Peroxisome Proliferator-Activated Receptor antagonists in colorectal and pancreatic cancer cell lines
AMMAZZALORSO, Alessandra;DE LELLIS, LAURA;FLORIO, ROSALBA;BRUNO, ISABELLA;DE FILIPPIS, Barbara;FANTACUZZI, MARIALUIGIA;GIAMPIETRO, Letizia;MACCALLINI, Cristina;PERCONTI, SILVIA;VERGINELLI, Fabio;CAMA, Alessandro;AMOROSO, Rosa
2017-01-01
Abstract
Recent studies report an interesting role of Peroxisome Proliferator-Activated Receptors (PPAR) antagonists in different tumor models, being these compounds able to perturb metabolism and viability in cancer cells. In this work the identification of a novel PPAR antagonist, showing inhibitory activity on PPARa and a weaker antagonism on PPARg, is described. The activity of this compound and of a series of chemical analogues was investigated in selected tumor cell lines, expressing both PPARa and PPARg. Data obtained show a dose-dependent cytotoxic effect of the novel PPAR antagonist in colorectal and pancreatic cancer models.File | Dimensione | Formato | |
---|---|---|---|
cbdd.13026.pdf
Solo gestori archivio
Descrizione: Research Letter
Tipologia:
PDF editoriale
Dimensione
602.01 kB
Formato
Adobe PDF
|
602.01 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.